Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks

Arias, Luis; Pujol, O.; Rubio, Marc; Caminal, Josep M.

doi:10.1007/s00417-005-0131-3

Cited by 44 publications

(34 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, in the group of juxtafoveal CNV (7 eyes) 4 eyes progressed to a subfoveal location during the follow-up of 12 months. Again a reduction of mean BCVA from 20/126 at baseline to 20/500 after a mean follow-up of 18 months was reported by Arias et al [77]. A long-term follow-up from 12 to 50 months (mean 26.1 months) of 15 eyes (10 with subfoveal, 5 with extra- or juxtafoveolar CNV) was presented by Heimann et al [35].…”

Section: Treatment Of Cnv Due To Other Forms Of Amd and Different Undmentioning

confidence: 97%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 1)

et al. 2007

View full text Add to dashboard Cite

Ocular photodynamic therapy (PDT) was introduced as a novel treatment for neovascular forms of age-related macular degeneration and choroidal neovascularization (CNV) secondary to pathologic myopia in the mid/end 1990s. The current treatment recommendations are based on the results of two large, prospective, multicenter, randomized clinical trials (Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Studies) and thousands of patients have been treated worldwide over the last years. Meanwhile, PDT has been performed in several other ocular pathologies with some remarkable results, however, with most reports being case reports and small case series without statistical significance. These extended applications include CNV secondary to choroiditis and retinochoroiditis, angioid streaks, central serous chorioretinopathy, retinal angiomatous proliferation, parafoveal telangiectasia or CNV associated with macular dystrophy and idiopathic CNV, as well as diseases without CNV, such as choroidal hemangioma, retinal hamartoma, choroidal melanoma, chronic central serous chorioretinopathy, angiomatous lesions secondary to systemic diseases, rubeosis iridis or neovascular glaucoma. To date, with the introduction of anti-VEGF therapy, the role of PDT will certainly change. However, it is reasonable to believe that it will maintain an important role in combination therapy due to its unique properties of selective vascular targeting. Therefore, it is essential for the ophthalmologist to be familiar with the extended applications and their modifications of treatment parameters. This review will summarize the standard and experimental applications of PDT based on our own results and the literature.

show abstract

Section: Treatment Of Cnv Due To Other Forms Of Amd and Different Undmentioning

confidence: 97%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 1)

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Other studies with longer follow-up also report enlarged CNV or disciform lesions in most patients with poor visual acuity of 20/600. 42,43 A study showed that the mean visual acuity decreased from 20/ 32 to o20/200 in nearly half the patients and only 13% was noted to have X20/63 at final follow-up. 44 Anti-angiogenic agents Owing to the rarity of this condition, single case reports are the prevalent source of treatment outcome data.…”

Section: Therapeutic Optionsmentioning

confidence: 99%

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Gupta

Elagouz

Sivaprasad

2009

Eye

View full text Add to dashboard Cite

Choroidal neovascularisation (CNV) is characterised by new blood vessel growth under the retina that usually results in significant visual impairment when the fovea is involved. Though CNV is more commonly associated with age-related macular degeneration (AMD), it can occur secondary to a variety of other diseases. Recent successes with anti-angiogenic therapies suggest that they may outperform other therapies for all types of CNV. As non-AMD-related CNV cases are rare, randomised controlled trials are often not possible. This review compares the less prevalent reports of non-AMD CNV and pools evidence on the success and limitations of a variety of therapies.

show abstract

“…Typically, the other causes of CNV affect working-age persons, are multifocal, sometimes juxta or extra-foveal, and can be recurrent [1,3]. In the past, lesions of CNV related to angioid streaks had a particularly poor prognosis with bad responses to photocoagulation [12] or photodynamic therapy (PDT) [13,14,15,16]. In the literature there are only a few reports of series of patients treated off-label with bevacizumab [17,18,19,20,21,22,23] or ranibizumab [23,24,25].…”

Section: Introductionmentioning

confidence: 99%

Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia

et al. 2010

View full text Add to dashboard Cite

Aim: Evaluation of safety and efficacy of intravitreal ranibizumab in the treatment of choroidal neovascularization (CNV) secondary to causes other than age-related macular degeneration (AMD) or pathological myopia (PM). Methods: Retrospective and multicentric analysis of 21 eyes with CNV. Nine eyes had angioid streaks, 5 inflammatory chorioretinal diseases, 3 central serous chorioretinopathy and 4 idiopathic CNV. Follow-ups lasted ≧3 months. Best-corrected visual acuity (BCVA), ocular coherence tomography (OCT) and fundus examination were assessed monthly. Results: Sixteen eyes (76%) completed 180 days of follow-up. Overall BCVA increased by +9.8 letters with treatment (p = 0.015). Visual acuity improvements ≧15 letters occurred in 43%. A significant reduction in OCT central thickness was observed. No cases of severe visual acuity loss, systemic or ocular side effects were registered. Conclusion: Short-term results of intravitreal ranibizumab for CNV unrelated to AMD or PM are encouraging. This treatment may constitute the only option for some of these patients.

show abstract

Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks

Abstract: PDT with verteporfin does not seem to be a good treatment for stabilization of VA and lesion size in CNV secondary to AS, although the overall results seem to be slightly better in the group of patients treated with PDT than in the control group.

Cited by 44 publications

References 9 publications

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 1)

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 1)

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia

Contact Info

Product

Resources

About